- Title: Rovi shares drop over possible contamination of Moderna COVID jab doses
- Date: 26th August 2021
- Summary: SAN SEBASTIAN DE LOS REYES, SPAIN (FILE) (REUTERS) ROVI SIGN OUTSIDE ROVI HEADQUARTERS NEAR MADRID VARIOUS OF ROVI EXTERIORS
- Embargoed: 9th September 2021 10:45
- Keywords: COVID vaccine Japan suspends Moderna Moderna Rovi coronavirus
- Location: SAN SEBASTIAN DE LOS REYES AND POZUELO DE ALARCON, SPAIN
- City: SAN SEBASTIAN DE LOS REYES AND POZUELO DE ALARCON, SPAIN
- Country: Spain
- Topics: Europe,Health/Medicine
- Reuters ID: LVA001ERX3UX3
- Aspect Ratio: 16:9
- Story Text: Spanish pharma company Rovi which bottles Moderna vaccines outside the United States said on Thursday (August 26) the possible contamination of vaccine doses is under investigation and appears limited to a few batches destined for Japan.
Shares in Rovi dropped 4.6% after Japan suspended the use of 1.63 million doses of Moderna Inc.'s COVID-19 vaccine on Thursday, more than a week after the domestic distributor received reports of contaminants in some vials.
Both Japan and Moderna said that no safety or efficacy issues had been identified and that the suspension was just a precaution. But the move prompted several Japanese companies to cancel worker vaccinations planned for Thursday.
"Moderna confirms having been notified of cases of particulate matter being seen in drug product vials of its COVID-19 vaccine," Moderna said in a statement.
"The company is investigating the reports and remains committed to working expeditiously with its partner, Takeda, and regulators to address this," it added, referring to Japan's Takeda Pharmaceutical , which distributes the vaccine in the country.
A Health Ministry official said Takeda first found out about the contaminated vials on Aug. 16 and reported the issue to the government on Wednesday. The delay was because Takeda needed time to gather information on which vials were affected and where they were in the country, the official said.
Moderna said the contamination could be due to a manufacturing issue in one of the production lines at its contract manufacturing site in Spain.
The suspension is a fresh setback for Moderna, whose partners had production delays last month that disrupted supplies to countries, including South Korea.
Moderna and Takeda did not immediately reply to Reuters' requests for comment.
Japan's defence ministry, which operates a mass vaccination site in Osaka, said shots from the lot in question, which contains 565,400 doses, had been used in the western prefecture between Aug. 6 and Aug. 20, but it did not say how many people were affected.
Moderna said that "out of an abundance of caution" it had put the lot in question and two adjacent lots on hold.
Takeda said it conducted an emergency examination after particulate matter was found in a lot of vaccine vials at an inoculation site.
Prime Minister Yoshihide Suga said on Thursday the country's inoculation plan would be little affected by the issue. A day earlier, he said about 60% of the public will be fully vaccinated by the end of September and the country had enough vaccines to provide booster doses if such a decision is taken.
Chief Cabinet Secretary Katsunobu Kato said there had been no cases reported of health issues related to contaminated shots administrated.
Japan Airlines said it had cancelled some COVID-19 vaccinations for its employees on Thursday after receiving Moderna vaccines with particulate matter.
Its rival ANA said about 4,700 shots of the halted Moderna lot had been used and it would stop all vaccination planned on Thursday.
Japan is battling its worst wave of infections, driven by the Delta variant, with new daily infections exceeding 25,000 for the first time this month. It has inoculated 54% of its population with at least one dose and fully vaccinated 43%, according to a Reuters vaccine tracker.
(Production: Catherine Macdonald, Marco Trujillo)
- Copyright Holder: FILE REUTERS (CAN SELL)
- Copyright Notice: (c) Copyright Thomson Reuters 2021. Open For Restrictions - http://about.reuters.com/fulllegal.asp
- Usage Terms/Restrictions: None